...survival (PFS). In MS, Merck KGaA discontinued one program, plovamer acetate, which was acquired from Peptimmune Inc....

...stage clinical deal was for exclusive rights to the Phase I MS compound PI-2301 from Peptimmune Inc....
...Bagsvaerd, Denmark Oncothyreon Inc. (NASDAQ:ONTY), Seattle, Wash. Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528), Osaka, Japan Peptimmune Inc....
...in Ph II to treat relapsing-remitting multiple sclerosis ¥1.5B ($19.5M) up front; undisclosed milestones Oct-2011 Peptimmune Inc....

...Development, where he started several IT companies. Bronstein was co-founder of autoimmune and inflammation company Peptimmune Inc....

...Merck Serono S.A. division acquired exclusive, worldwide rights to multiple sclerosis (MS) candidate PI-2301 from Peptimmune...
...disclosed (see BioCentury, Jan. 19, 2009 & March 28, 2011). Merck KGaA (Xetra:MRK), Darmstadt, Germany Peptimmune Inc....

...acid random sequence peptide copolymer that completed Phase Ib testing to treat multiple sclerosis (MS). Peptimmune Inc....

...obesity company Elixir Pharmaceuticals Inc. ; renal company Proteon Therapeutics Inc. ; and autoimmune company Peptimmune Inc....

...In the petition, Peptimmune provided data characterizing Copaxone based on its own methods of characterization. Peptimmune...

...for Treatment and Research in Multiple Sclerosis meeting in Dusseldorf on Sept. 10. In January, Peptimmune...
...exclusive, worldwide rights to develop and commercialize PI-2301 to treat MS (see BioCentury, Jan. 19). Peptimmune Inc....

...The other two were for renal company Proteon Therapeutics Inc. in March and autoimmune company Peptimmune Inc....

...Indeed, this isn't the first introduction MPM has made. In one disclosed deal in January, Peptimmune...